文献速递造血干细胞移植与细胞治疗血栓与止血

异基因造血干细胞移植后血栓性微血管病的危险因素与适当治疗策略

Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.
PubMed 文献 · Blood Adv · 2020-01-01

这项由京都干细胞移植组开展的多中心回顾性队列研究纳入14家机构2425例接受异基因造血干细胞移植的血液病患者,121例(5.0%)在移植后中位第35天发生移植相关血栓性微血管病(TA-TMA),其与总生存较差显著相关(HR 4.93)。多因素分析确定移植前后危险因素包括体能状态较差(HR 1.69)、HLA不合(HR 2.17)、3-4级急性移植物抗宿主病(HR 4.02)、曲霉感染(HR 2.29)和肝静脉闭塞病/肝窦阻塞综合征(HR 4.47);继续或谨慎减量钙调神经磷酸酶抑制剂较传统换用糖皮质激素的缓解率更优(64.7% vs 20.0%)。

要点

  • TA-TMA发生率为5.0%,中位发生于移植后第35天,与总生存较差显著相关(HR 4.93)。
  • 多因素分析显示3-4级aGVHD(HR 4.02)、VOD/SOS(HR 4.47)、HLA不合(HR 2.17)、曲霉感染(HR 2.29)、体能状态较差(HR 1.69)为危险因素。
  • 继续或谨慎减量CNI较换用糖皮质激素的缓解率显著更优(64.7% vs 20.0%)。

核心结论

  • 研究确定了TA-TMA的危险因素及较适当的治疗策略,所述治疗策略未来可能改善TA-TMA患者的结局。

研究设计与样本

  • 由京都干细胞移植组(KSCTG)开展的多中心回顾性队列研究,纳入14家机构共2425例患者。
  • 所有患者年龄≥16岁、患血液病、于2000年后接受异基因造血干细胞移植。

主要发现

  • 121例(5.0%)患者在中位第35天观察到TA-TMA,并与总生存较差显著相关(HR 4.93)。
  • 多因素分析确定的移植前后显著危险因素包括体能状态较差(HR 1.69)、HLA不合(HR 2.17)、3-4级急性移植物抗宿主病(HR 4.02)、曲霉感染(HR 2.29)和肝静脉闭塞病/肝窦阻塞综合征(HR 4.47)。
  • 继续或谨慎减量钙调神经磷酸酶抑制剂的缓解率和总生存显著优于传统换用糖皮质激素策略(缓解率64.7% vs 20.0%)。

临床怎么用

  • 作者在总结中提出,所述继续或谨慎减量钙调神经磷酸酶抑制剂的治疗策略未来可能改善TA-TMA患者的结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, so far, no large cohort study determined the risk factors and the most effective therapeutic strategies for TA-TMA. Thus, the present study aimed to clarify these clinical aspects based on a large multicenter cohort. This retrospective cohort study was performed by the Kyoto Stem Cell Transplantation Group (KSCTG). A total of 2425 patients were enrolled from 14 institutions. All patients were aged ≥16 years, presented with hematological diseases, and received allo-HSCT after the year 2000. TA-TMA was observed in 121 patients (5.0%) on day 35 (median) and was clearly correlated with inferior overall survival (OS) (hazard ratio [HR], 4.93). Pre- and post-HSCT statistically significant risk factors identified by multivariate analyses included poorer performance status (HR, 1.69), HLA mismatch (HR, 2.17), acute graft-versus-host disease (aGVHD; grades 3-4) (HR, 4.02), Aspergillus infection (HR, 2.29), and veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS; HR, 4.47). The response rate and OS significantly better with the continuation or careful reduction of calcineurin inhibitors (CNI) than the conventional treatment strategy of switching from CNI to corticosteroids (response rate, 64.7% vs 20.0%). In summary, we identified the risk factors and the most appropriate therapeutic strategies for TA-TMA. The described treatment strategy could improve the outcomes of patients with TA-TMA in the future.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Matsui H, Arai Y, Imoto H, et al. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv. 2020. PMID: 32658984. doi:10.1182/bloodadvances.2020002007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。